Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Current Investments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash & Current Investments for 4 consecutive years, with $441.1 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 17.04% year-over-year to $441.1 million; the TTM value through Dec 2025 reached $441.1 million, down 17.04%, while the annual FY2025 figure was $441.1 million, 17.04% down from the prior year.
  • Cash & Current Investments was $441.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $451.6 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $558.4 million in Q3 2024, with the low at $262.7 million in Q1 2022.
  • Historically, Cash & Current Investments has averaged $405.6 million across 4 years, with a median of $397.2 million in 2022.
  • Biggest YoY gain for Cash & Current Investments was 48.77% in 2025; the steepest drop was 19.13% in 2025.
  • Over 4 years, Cash & Current Investments stood at $342.3 million in 2022, then grew by 7.03% to $366.3 million in 2023, then skyrocketed by 45.14% to $531.7 million in 2024, then decreased by 17.04% to $441.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $441.1 million in Q4 2025, $451.6 million in Q3 2025, and $453.1 million in Q2 2025.